Skip to content
Snippets Groups Projects
Commit b633ae85 authored by Timofej Paramonov Bliki's avatar Timofej Paramonov Bliki :heart:
Browse files

Merge branch 'fixing-description-AGAIN' into 'main' 

Fixed image placement and sizing. Fixed last term in description.

See merge request !54
parents c1aee1f3 cb69d018
No related branches found
No related tags found
1 merge request!54Fixed image placement and sizing. Fixed last term in description.
Pipeline #515810 passed
Stage: build
Stage: deploy
Hide whitespace changes
Inline Side-by-side
wiki/pages/description.html
+ 74
− 127
View file @ b633ae85
......@@ -9,138 +9,85 @@
p {
font-size: 20px
}
.center {
display: flex;
justify-content: center;
}
.med-img {
width:auto;
height:auto;
max-width: max(40%, 400px);
}
.small-img {
width:auto;
height:auto;
max-width: max(30%, 400px);
}
</style>
<div class="px-lg-5">
<div class="row mt-4">
<div class="col-lg-8">
<p>
The 2024 Radboud iGEM Team, the first team of our university, is dedicated to addressing the daily challenges faced by patients with hemophilia A.
This condition is caused by a genetic mutation in the FVIII gene on the X-chromosome, which prevents liver sinusoidal endothelial cells (LSECs) from producing coagulation factor VIII, a crucial protein in the blood clotting process.
Our project aims to develop a more effective and comfortable treatment for this genetic disorder compared to current methods.
</p>
</div>
<div class="col-lg-4">
<img src="https://static.igem.wiki/teams/5342/images/description/desc1.jpg" alt="Hemophilia A" class="img-fluid">
</div>
</div>
<div class="row mt-4">
<div class="col-lg-8">
<p>
We propose the creation of LNP containing mRNAs that encode the coagulation factor VIII protein.
LNPs administered into the bloodstream travel to the liver and target LSECs with the help of surface proteins.
Once inside the cells, the vesicles will release the mRNAs, leading to the production of coagulation factor VIII.
This approach enables patients to produce their own coagulation factor VIII, eliminating the need for frequent injections of plasma-derived or recombinant proteins.
</p>
</div>
<div class="col-lg-4">
<img src="https://static.igem.wiki/teams/5342/images/home/infinityf-method.webp" alt="Vesicle structure" class="img-fluid">
</div>
</div>
<div class="row mt-4">
<div class="col-lg-8">
<p>
Presently, patients experience large fluctuations in blood coagulation factor VIII levels after injections, leading to brief stable periods followed by rapid declines.
This necessitates frequent injections and risks sudden drops in coagulation factor VIII protein levels, which can trigger hemophilia symptoms.
Our mRNA delivery system is expected to provide more stable and prolonged protein levels, reducing the frequency of treatments.
</p>
</div>
<div class="col-lg-4">
<img src="https://static.igem.wiki/teams/5342/images/description/desc3.png" alt="Graph that demonstrates rapid declines" class="img-fluid">
</div>
</div>
<div class="row mt-4">
<div class="col-lg-8">
<p>
Additionally, our system offers an alternative to intravenous administration.
Recognizing the discomfort of this method, we propose a nasal spray delivery system using hydrogel and LNPs, which allows mRNA absorption through the nasal epithelium.
We also try to eliminate the risk of viral infections, such as HIV and HCV, which can occur with human plasma-derived FVIII treatments.
While rare, such infections are possible.
</p>
</div>
<div class="col-lg-4">
<img src="https://static.igem.wiki/teams/5342/images/description/desc4.jpg" alt="Nasal spray" class="img-fluid w-50">
</div>
</div>
<div class="row mt-4">
<div class="col-lg-8">
<p>
Hemophilia is a widespread condition affecting approximately 1,125,000 people worldwide and we, as a group of young scientists, are committed to enhancing the quality of life for these patients.
In severe cases, hemophilia can lead to fatal blood loss, but even minor inconveniences, like restricted physical activities, significantly impact patients' lives.
Our project aspires to contribute to a better quality of life for those affected by hemophilia, addressing both major and minor challenges of the current treatment landscape.
</p>
</div>
<div class="col-lg-4">
<img src="https://static.igem.wiki/teams/5342/images/description/desc5.jpg" alt="Human holding heart, symbolically representing safety" class="img-fluid">
</div>
</div>
<div class="row mt-4">
<div class="col">
<h2>Reference Articles:</h2>
<ol>
<li>Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver:
<br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7909888/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7909888/</a> </li>
<li>Systemic delivery of factor IX messenger RNA for protein replacement therapy:
<br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347596/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347596/</a> </li>
<li>Advanced Strategies for Overcoming Endosomal/Lysosomal Barrier in Nanodrug Delivery:
<br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208951/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208951/</a> </li>
</ol>
</div>
</div>
<div>
<p>
The 2024 Radboud iGEM Team, the first team of our university, is dedicated to addressing the daily challenges faced by patients with hemophilia A.
This condition is caused by a genetic mutation in the FVIII gene on the X-chromosome, which prevents liver sinusoidal endothelial cells (LSECs) from producing coagulation factor VIII, a crucial protein in the blood clotting process.
Our project aims to develop a more effective and comfortable treatment for this genetic disorder compared to current methods.
</p>
</div>
<!-- This comment is to preserve the template description.html, which will be deleted once this file is complete.
<div class="row mt-4">
<div class="col">
<div class="bd-callout bd-callout-info">
<h4>Bronze Medal Criterion #3</h4>
<p>Describe how and why you chose your iGEM project.</p>
<hr>
<p>Please see the <a href="https://competition.igem.org/judging/medals">2024 Medals Page</a> for more information.</p>
</div>
</div>
<div class="center">
<img src="https://static.igem.wiki/teams/5342/images/description/desc1.jpg" alt="Hemophilia A" class="med-img ">
</div>
<div class="row mt-4">
<div class="col-lg-8">
<h2>What should this page contain?</h2>
<hr>
<ul>
<li>A clear and concise description of your project.</li>
<li>A detailed explanation of why your team chose to work on this particular project.</li>
<li>References and sources to document your research.</li>
<li>Use illustrations and other visual resources to explain your project.</li>
</ul>
</div>
<div class="col-lg-4">
<h2>Inspirations</h2>
<hr>
<ul>
<li><a href="https://2022.igem.wiki/dtu-denmark/description">2022 DTU-Denmark</a></li>
<li><a href="https://2019.igem.org/Team:ITESO_Guadalajara/Description">2019 ITESO Guadalajara</a></li>
<li><a href="https://2020.igem.org/Team:Technion-Israel/Description">2020 Technion Israel</a></li>
<li><a href="https://2020.igem.org/Team:Botchan_Lab_Tokyo/Description">2020 Botchan Lab Tokyo</a></li>
<li><a href="https://2020.igem.org/Team:St_Andrews/Description">2020 St Andrews</a></li>
<li><a href="https://2020.igem.org/Team:MIT/Description">2020 MIT</a></li>
</ul>
</div>
<div>
<p>
We propose the creation of ionizable lipid nanoparticles (LNPs) containing mRNAs that encode the coagulation factor VIII protein.
LNPs administered into the bloodstream travel to the liver and target LSECs with the help of surface proteins.
Once inside the cells, the LNPs will release the mRNAs, leading to the production of coagulation factor VIII.
This approach enables patients to produce their own coagulation factor VIII, eliminating the need for frequent injections of plasma-derived or recombinant proteins.
</p>
</div>
<div class="row mt-4">
<div class="col-lg-8">
<h2>Some advice</h2>
<hr>
<p>We encourage you to put up a lot of information and content on your wiki, but we also encourage you to include summaries as much as possible. If you think of the sections in your project description as the sections in a publication, you should try to be concise, accurate, and unambiguous in your achievements. Your Project Description should include more information than your project abstract.</p>
</div>
<div class="col-lg-4">
<h2>References</h2>
<hr>
<p>iGEM teams are encouraged to record references you use during the course of your research. They should be posted somewhere on your wiki so that judges and other visitors can see how you thought about your project and what works inspired you.</p>
</div>
<div class="center">
<img src="https://static.igem.wiki/teams/5342/images/home/infinityf-method.webp" alt="Vesicle structure" class="med-img ">
</div>
-->
<div>
<p>
Presently, patients experience large fluctuations in blood coagulation factor VIII levels after injections, leading to brief stable periods followed by rapid declines.
This necessitates frequent injections and risks sudden drops in coagulation factor VIII protein levels, which can trigger hemophilia symptoms.
Our mRNA delivery system is expected to provide more stable and prolonged protein levels, reducing the frequency of treatments.
</p>
</div>
<div class="center">
<img src="https://static.igem.wiki/teams/5342/images/description/desc3.png" alt="Graph that demonstrates rapid declines" class="med-img ">
</div>
<div>
<p>
Additionally, our system offers an alternative to intravenous administration.
Recognizing the discomfort of this method, we propose a nasal spray delivery system using hydrogel and LNPs, which allows mRNA absorption through the nasal epithelium.
We also try to eliminate the risk of viral infections, such as HIV and HCV, which can occur with human plasma-derived FVIII treatments.
While rare, such infections are possible.
</p>
</div>
<div class="center">
<img src="https://static.igem.wiki/teams/5342/images/description/desc4.jpg" alt="Nasal spray" class="small-img">
</div>
<div>
<p>
Hemophilia is a widespread condition affecting approximately 1,125,000 people worldwide and we, as a group of young scientists, are committed to enhancing the quality of life for these patients.
In severe cases, hemophilia can lead to fatal blood loss, but even minor inconveniences, like restricted physical activities, significantly impact patients' lives.
Our project aspires to contribute to a better quality of life for those affected by hemophilia, addressing both major and minor challenges of the current treatment landscape.
</p>
</div>
<div class="center">
<img src="https://static.igem.wiki/teams/5342/images/description/desc5.jpg" alt="Human holding heart, symbolically representing safety" class="med-img">
</div>
<div>
<h2>Reference Articles:</h2>
<ol>
<li>Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver:
<br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7909888/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7909888/</a> </li>
<li>Systemic delivery of factor IX messenger RNA for protein replacement therapy:
<br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347596/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347596/</a> </li>
<li>Advanced Strategies for Overcoming Endosomal/Lysosomal Barrier in Nanodrug Delivery:
<br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208951/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208951/</a> </li>
</ol>
</div>
{% endblock %}
0% or .
You are about to add 0 people to the discussion. Proceed with caution.
Finish editing this message first!
Please register or to comment